Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSI OTCMKTS:CBWTF NASDAQ:MXCT NASDAQ:NRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$3.12+8.3%$2.78$2.01▼$6.33$397.98M2.013.01 million shs8.71 million shsCBWTFCannabis Wheaton Income$0.10-8.8%$0.07$0.02▼$0.13$135.13M1.041.67 million shs1.25 million shsMXCTMaxCyte$2.02-6.0%$2.22$2.00▼$5.20$214.96M1.23615,011 shs387,728 shsNRCNational Research$14.22-4.9%$15.30$9.76▼$27.07$324M0.4589,789 shs77,099 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci0.00%+16.85%+13.45%+0.97%-28.77%CBWTFCannabis Wheaton Income0.00%+5.25%+72.04%+75.35%+298.02%MXCTMaxCyte0.00%-9.01%-4.27%-22.61%-59.76%NRCNational Research0.00%-10.90%-15.51%+34.91%-42.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABSIAbsci1.6116 of 5 stars3.51.00.00.00.61.70.6CBWTFCannabis Wheaton Income0.4343 of 5 stars0.03.00.00.00.60.01.3MXCTMaxCyte3.0748 of 5 stars3.54.00.00.02.51.70.6NRCNational Research2.492 of 5 stars0.04.01.70.01.82.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 3.00Buy$8.40169.23% UpsideCBWTFCannabis Wheaton Income 0.00N/AN/AN/AMXCTMaxCyte 3.00Buy$7.50271.29% UpsideNRCNational Research 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CBWTF, ABSI, NRC, and MXCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ABSIAbsciMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.005/14/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$4.53M87.86N/AN/A$1.56 per share2.00CBWTFCannabis Wheaton Income$89.29M1.50N/AN/A$0.06 per share1.67MXCTMaxCyte$38.63M5.56N/AN/A$1.95 per share1.04NRCNational Research$143.06M2.26$1.33 per share10.66$1.36 per share10.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$103.11M-$0.92N/AN/AN/A-2,232.13%-53.69%-45.89%8/13/2025 (Estimated)CBWTFCannabis Wheaton Income-$11.93M$0.0110.04∞N/A16.56%18.53%8.13%N/AMXCTMaxCyte-$41.06M-$0.40N/AN/AN/A-110.92%-19.90%-17.24%8/6/2025 (Estimated)NRCNational Research$24.78M$1.0313.81∞N/A17.14%71.33%18.67%7/28/2025 (Estimated)Latest CBWTF, ABSI, NRC, and MXCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ABSIAbsci-$0.19N/AN/AN/A$1.39 millionN/A8/6/2025Q2 2025MXCTMaxCyte-$0.10N/AN/AN/A$9.57 millionN/A5/15/2025Q1 2025CBWTFCannabis Wheaton IncomeN/A$0.01N/A$0.01N/AN/A5/13/2025Q1 2025ABSIAbsci-$0.23-$0.21+$0.02-$0.21$1.07 million$1.18 million5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million4/28/2025Q1 2025NRCNational ResearchN/A$0.25N/A$0.25N/A$33.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/ACBWTFCannabis Wheaton IncomeN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/ANRCNational Research$0.483.38%N/A46.60%N/ALatest CBWTF, ABSI, NRC, and MXCT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/25/2025NRCNational Researchquarterly$0.124.1%6/27/20256/27/20257/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsciN/A5.725.72CBWTFCannabis Wheaton Income0.020.680.34MXCTMaxCyteN/A12.2311.58NRCNational Research1.980.540.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%CBWTFCannabis Wheaton IncomeN/AMXCTMaxCyte68.81%NRCNational Research47.26%Insider OwnershipCompanyInsider OwnershipABSIAbsci10.49%CBWTFCannabis Wheaton Income4.60%MXCTMaxCyte3.30%NRCNational Research8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210127.56 million114.18 millionOptionableCBWTFCannabis Wheaton Income3691.34 billion1.27 billionNot OptionableMXCTMaxCyte80106.42 million102.90 millionOptionableNRCNational Research49022.78 million20.94 millionOptionableCBWTF, ABSI, NRC, and MXCT HeadlinesRecent News About These CompaniesInternational research consortium using AI to boost mining sectorJuly 17 at 12:48 PM | canadianminingjournal.comCFvD MP held video talks with Russian politicians: NRCJuly 17 at 12:48 PM | dutchnews.nlDAssam Wants NRC Considered In EC’s Voter Roll Revision, Amid Bihar RowJuly 17 at 12:48 PM | outlookindia.comEmbattled US scientific society names palaeontologist to top jobJuly 15, 2025 | nature.comNAmid Bihar row, Assam wants NRC considered in EC’s voter roll revisionJuly 15, 2025 | indianexpress.comICanadian Scientists Use D-Wave in Quantum-AI SimulationsJuly 11, 2025 | insidehpc.comIDOGE comes to the NRCJuly 11, 2025 | thehill.comTArunachal minister presents 10-point agenda at ICAR AGM, pushes for skill based agri-educationJuly 8, 2025 | msn.comGlycovax Pharma launches a highly performant SLA AdjuvantJuly 8, 2025 | finance.yahoo.comAward-winning Notts County player revealed as new NRC AmbassadorJuly 5, 2025 | westbridgfordwire.comWNRC: No major misuse of funds by Holtec International at Palisades Nuclear PlantJuly 5, 2025 | msn.comCanada, UK Join Forces to Boost Semiconductor ChainJuly 4, 2025 | miragenews.comMCanada and UK partner to build a stronger semiconductor supply chainJuly 4, 2025 | canada.caCNational Research (NASDAQ:NRC) Shares Cross Above 200 Day Moving Average - Here's What HappenedJuly 3, 2025 | marketbeat.comTurmoil at US science academy as Trump cuts force layoffsJuly 1, 2025 | nature.comNCanada, Germany Conclude Milestone Year as Eureka Co-chairsJune 30, 2025 | miragenews.comMCanada and Germany wrap up a milestone year of global collaboration as Eureka Network co-chairsJune 30, 2025 | canada.caCICAR-KVK Phek, NRC Mithun host Mithun MahotsavJune 28, 2025 | morungexpress.comMNRC National Research Corporation - Seeking AlphaJune 26, 2025 | seekingalpha.comNational Research Solidifies Dividend Amid Insider Buying and Contract GrowthJune 26, 2025 | msn.comOxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for BunyaviricetesJune 25, 2025 | pharmiweb.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBWTF, ABSI, NRC, and MXCT Company DescriptionsAbsci NASDAQ:ABSI$3.12 +0.24 (+8.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.14 +0.01 (+0.48%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Cannabis Wheaton Income OTCMKTS:CBWTF$0.10 -0.01 (-8.82%) As of 07/18/2025 03:59 PM EasternAuxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.MaxCyte NASDAQ:MXCT$2.02 -0.13 (-6.05%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.04 +0.02 (+0.74%) As of 07/18/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.National Research NASDAQ:NRC$14.22 -0.73 (-4.88%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.37 +0.15 (+1.08%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
